Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Holly M. Alley"'
Autor:
Donald P. McDonnell, Jay C. Strum, Scott A. Lawrence, Rigel J. Kishton, Kimberly J. Cocce, Peter S. Winter, Rachid Safi, Hannah S. White, Victoria O. Haney, Holly M. Alley, Alexander P. Yllanes, John D. Norris, Suzanne E. Wardell, James P. Stice
Resistance to second-generation androgen receptor (AR) antagonists and CYP17 inhibitors in patients with castration-resistant prostate cancer (CRPC) develops rapidly through reactivation of the androgen signaling axis and has been attributed to AR ov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::997103967b585ac8b172658ecb3b7484
https://doi.org/10.1158/1541-7786.c.6541489
https://doi.org/10.1158/1541-7786.c.6541489
Autor:
Donald P. McDonnell, Jay C. Strum, Scott A. Lawrence, Rigel J. Kishton, Kimberly J. Cocce, Peter S. Winter, Rachid Safi, Hannah S. White, Victoria O. Haney, Holly M. Alley, Alexander P. Yllanes, John D. Norris, Suzanne E. Wardell, James P. Stice
Contains legends to supplementary figures.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d46f3a7d6a33693b28b5123409ea4c0b
https://doi.org/10.1158/1541-7786.22516804.v1
https://doi.org/10.1158/1541-7786.22516804.v1
Autor:
Donald P. McDonnell, Jay C. Strum, Scott A. Lawrence, Rigel J. Kishton, Kimberly J. Cocce, Peter S. Winter, Rachid Safi, Hannah S. White, Victoria O. Haney, Holly M. Alley, Alexander P. Yllanes, John D. Norris, Suzanne E. Wardell, James P. Stice
Supplemental Figure 1. The effects of G1T28 are due to CDK4/6 inhibition. Supplemental Figure 2. Analysis of pharmacodynamics endpoints indicates on-target activity in 22Rv1 tumors. A. Supplemental Figure 3. G1T38 and G128 have similar in vitro effic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01d35094806626b4a693938067925dfd
https://doi.org/10.1158/1541-7786.22516801.v1
https://doi.org/10.1158/1541-7786.22516801.v1
Autor:
Shunqiang Li, Donald P. McDonnell, John D. Norris, Jin-Ping Lai, Robert Crowder, Jieya Shao, Elizabeth Griffin, Tina Primeau, Kim T. Arndt, Stephen G. Dann, Todd VanArsdale, Koleen Eisele, Holly M. Alley, Matthew J. Ellis, Suzanne E. Wardell
Supplemental figure 3: SERDs and palbociclib inhibit breast cancer cell proliferation by independent mechanisms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::913466b83847b02760d8832503645b8d
https://doi.org/10.1158/1078-0432.22454691.v1
https://doi.org/10.1158/1078-0432.22454691.v1
Autor:
Shunqiang Li, Donald P. McDonnell, John D. Norris, Jin-Ping Lai, Robert Crowder, Jieya Shao, Elizabeth Griffin, Tina Primeau, Kim T. Arndt, Stephen G. Dann, Todd VanArsdale, Koleen Eisele, Holly M. Alley, Matthew J. Ellis, Suzanne E. Wardell
Supplemental figure 4: Evaluation of pharmacodynamics endpoints confirms on target activity of SERDs and palbociclib, resulting in sustained inhibition of tumors receiving both treatments
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ee29c5e6c07b5a865bf126f1bef796e
https://doi.org/10.1158/1078-0432.22454688
https://doi.org/10.1158/1078-0432.22454688
Autor:
Shunqiang Li, Donald P. McDonnell, John D. Norris, Jin-Ping Lai, Robert Crowder, Jieya Shao, Elizabeth Griffin, Tina Primeau, Kim T. Arndt, Stephen G. Dann, Todd VanArsdale, Koleen Eisele, Holly M. Alley, Matthew J. Ellis, Suzanne E. Wardell
Supplemental figure 1: SERDs and SERMs differ in their ability to inhibit ER-dependent stimulation of breast cancer cell proliferation by growth factors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45421649f6c61cc430618d3b84ec6afd
https://doi.org/10.1158/1078-0432.22454700
https://doi.org/10.1158/1078-0432.22454700
Autor:
Shunqiang Li, Donald P. McDonnell, John D. Norris, Jin-Ping Lai, Robert Crowder, Jieya Shao, Elizabeth Griffin, Tina Primeau, Kim T. Arndt, Stephen G. Dann, Todd VanArsdale, Koleen Eisele, Holly M. Alley, Matthew J. Ellis, Suzanne E. Wardell
Supplemental figure 2: SERDs inhibit the constitutive activity of the clinically relevant Y537N,D538G ESR1 double mutant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53e5398bfcdac49fc14ce14291926781
https://doi.org/10.1158/1078-0432.22454697.v1
https://doi.org/10.1158/1078-0432.22454697.v1
Autor:
Shunqiang Li, Donald P. McDonnell, John D. Norris, Jin-Ping Lai, Robert Crowder, Jieya Shao, Elizabeth Griffin, Tina Primeau, Kim T. Arndt, Stephen G. Dann, Todd VanArsdale, Koleen Eisele, Holly M. Alley, Matthew J. Ellis, Suzanne E. Wardell
Supplemental figure 5: IHC analysis of treated PDX tumors indicated on-target activity of bazedoxifene and palbociclib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::741a8d0744eed5814f3385c071daffe5
https://doi.org/10.1158/1078-0432.22454685
https://doi.org/10.1158/1078-0432.22454685
Autor:
Holly M. Alley, James P. Stice, Suzanne E. Wardell, Donald P. McDonnell, Ching-Yi Chang, Abigail B. McLeod
Publikováno v:
The Prostate. 78:266-277
Background Whereas the androgen receptor (AR) signaling axis remains a therapeutic target in castration-resistant prostate cancer (CRPC), the emergence of AR mutations and splice variants as mechanisms underlying resistance to contemporary inhibitors
Autor:
Rigel J. Kishton, Jay C. Strum, Holly M. Alley, Alexander P. Yllanes, James P. Stice, Scott A. Lawrence, Donald P. McDonnell, Kimberly J. Cocce, Rachid Safi, Suzanne E. Wardell, John D. Norris, Hannah S. White, Victoria Haney, Peter S. Winter
Publikováno v:
Molecular Cancer Research. 15:660-669
Resistance to second-generation androgen receptor (AR) antagonists and CYP17 inhibitors in patients with castration-resistant prostate cancer (CRPC) develops rapidly through reactivation of the androgen signaling axis and has been attributed to AR ov